double-blind random trial ketotifen versu placebo earli diffus scleroderma efficaci mast cell-stabil drug ketotifen scleroderma prospect double-blind placebo-control trial patient signific improv clinic paramet pulmonari function global assess cell releas pruritu group activ drug six month treatment ketotifen mg/day appar benefit patient earli scleroderma unabl role mast cell scleroderma mast cell suppress 